Biocon gets notice of compliance from Health Canada for two biosimilars
2026-04-21
·
via Company News: Companies Analysis, Updates & Insights | The HinduBusinessLine
Health Canada has granted a notice of compliance (NOC) for Bosaya (denosumab), a biosimilar to Prolia, and Vevzuo (denosumab), a biosimilar to Xgeva, on April 3, 2026, Biocon Ltd said in a regulatory filing
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。